Lupin Pharmaceuticals voluntarily recalled 12,480 bottles of its Paroxetine extended-release antidepressant tablets, reports The Economic Times.
Here are three things to know.
- The 12.5 milligram dose of the medication is being pulled off the market over failed dissolution specifications.
- Paroxetine is used to treat patients with depression, panic disorder and social anxiety disorder.
- The Food and Drug Administration labeled the recall as a Class III event, meaning the quality issue is not likely to cause adverse health risks to patients.
More articles on supply chain:
Herbal coffee recalled for containing erectile dysfunction drug ingredien
Puma Biotech earns FDA approval for breast cancer drug
A supply chain expert on what your performance dashboard is missing